This licensing agreement was written because Radient has no other way of getting any money.
UNI has no incentive to renegotiate. They will not, unless they decide that they can not profit from DR-70.
RXPC cannot chuck the whole thing away if UNI pays the $100,000 annual royalty on time. There is no loophole that benefits Radient if they want out, other than refusing to transfer the technology -- in which case they will have defrauded UNI and they will have only received $20,000, because UNI does not have to pay the other $80,000 for 2013 until "after tech transfer training and commercial-scale trial-run production for Onko-Sure (DR-70)."
Is that what you think Radient intends? Get $20,000 and then fail to deliver? Because that is the only way they can "chuck the whole thing away."
Also, please describe a "Worst Condition Basis" that is worse than the current condition. Thanks in advance.
